There are 2789 resources available
Yes
Presenter: Cristina Saura Manich
Session: All patients with newly diagnosed mBC should receive a comprehensive profiling using multigene sequencing
Resources:
Slides
Webcast
No
Presenter: Evandro de Azambuja
Session: All patients with newly diagnosed mBC should receive a comprehensive profiling using multigene sequencing
Resources:
Slides
Webcast
1040O - Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
Presenter: Jeffrey Weber
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1037O - MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
Presenter: Helen Gogas
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1O - Harnessing innate immunity in cancer therapies: The example of natural killer cell engagers
Presenter: Eric Vivier
Session: Proffered Paper session - Basic science
Resources:
Abstract
Slides
Webcast
2O - Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties
Presenter: Baiyong Li
Session: Proffered Paper session - Basic science
Resources:
Abstract
Slides
Webcast
3O - Patient-derived micro-organospheres (MOS) recapitulate tumor microenvironment and heterogeneity for precision oncology
Presenter: Shengli Ding
Session: Proffered Paper session - Basic science
Resources:
Abstract
Slides
Webcast
1800O - Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
Presenter: Álvaro Quintanal-Villalonga
Session: Proffered Paper session - Basic science
Resources:
Abstract
Slides
Webcast
LBA20 - FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
Presenter: Chiara Cremolini
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Webcast
383O - MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Webcast